Double-Drug attack: new combo targets tough lung cancer
NCT ID NCT03122717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and feasible for people with advanced EGFR-mutant non-small cell lung cancer who have not taken similar drugs before. About 48 participants will receive the combination for up to 6 months. Researchers will track how many complete the full course, side effects, and whether tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- osimertinib (Tagrisso) and gefitinib (Iressa)
- What this could lead to
- If successful, this combination could offer a more effective treatment option for people with advanced EGFR-mutant lung cancer, potentially improving tumor shrinkage and delaying progression.
- What could go wrong
- This is an early-phase trial with only 48 participants, so results may not apply broadly. Combining two targeted drugs may increase side effects, and it is unclear if the combination is better than standard single-drug therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?